Literature DB >> 20439644

Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12.

Christine J Harrison1, Robert K Hills, Anthony V Moorman, David J Grimwade, Ian Hann, David K H Webb, Keith Wheatley, Siebold S N de Graaf, Eva van den Berg, Alan K Burnett, Brenda E S Gibson.   

Abstract

PURPOSE: Karyotype is an independent indicator of prognosis in acute myeloid leukemia (AML) that is widely applied to risk-adapted therapy. Because AML is rare in children, the true prognostic significance of individual chromosomal abnormalities in this age group remains unclear. PATIENTS AND METHODS: This cytogenetic study of 729 childhood patients classified them into 22 subgroups and evaluated their incidence and risk.
RESULTS: Rearrangements of 11q23 were the most frequent abnormality found in approximately 16% of patients, with 50% of these in infants. The outcome for all patients with 11q23 abnormalities was intermediate; no difference was observed for those with t(9;11)(p21-22;q23). The core binding factor leukemias with the translocations t(8;21)(q22;q22) and inv(16)(p13q22) occurred at incidences of 14% and 7%, respectively, predominantly in older children, and their prognosis was favorable. An adverse outcome was observed in patients with monosomy 7, abnormalities of 5q, and t(6;9)(p23;q34). Abnormalities of 3q and complex karyotypes, in the absence of favorable-risk features, have been associated with an adverse outcome in adults, but the results were not significant in this childhood series. However, the presence of 12p abnormalities predicted a poor outcome.
CONCLUSION: Because the spectrum of chromosomal changes and their risk association seem to differ between children and adults with AML, biologic differences are emerging, which will contribute to the redefinition of risk stratification for different age groups in the future.

Entities:  

Mesh:

Year:  2010        PMID: 20439644     DOI: 10.1200/JCO.2009.24.8997

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  84 in total

1.  Unrelated cord blood transplantation for childhood acute myelogenous leukemia: The influence of cytogenetic risk group stratification.

Authors:  G Michel; R Cunha; A Ruggeri; T A O'Brien; H Bittencourt; J H Dalle; F Locatelli; A P Iori; M Mauad; C Oudin; F Giannotti; F Volt; E Gluckman; P Bader; V Rocha
Journal:  Leukemia       Date:  2015-09-15       Impact factor: 11.528

Review 2.  Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia.

Authors:  Yahya Daneshbod; Leila Kohan; Vahideh Taghadosi; Olga K Weinberg; Daniel A Arber
Journal:  Curr Treat Options Oncol       Date:  2019-02-11

3.  BCOR and BCORL1 mutations in pediatric acute myeloid leukemia.

Authors:  Jasmijn D E de Rooij; Marry M van den Heuvel-Eibrink; Malou C H Hermkens; Lonneke J Verboon; Susan T C J M Arentsen-Peters; Maarten Fornerod; Andre Baruchel; Jan Stary; Dirk Reinhardt; Valerie de Haas; Rob Pieters; C Michel Zwaan
Journal:  Haematologica       Date:  2015-01-16       Impact factor: 9.941

4.  Value of multifaced approach diagnosis and classification of acute leukemias.

Authors:  Silvana Angelescu; Nicoleta Mariana Berbec; Andrei Colita; Doina Barbu; Anca Roxana Lupu
Journal:  Maedica (Buchar)       Date:  2012-09

5.  Prognostic significance of B-cell lymphoma 2 expression in acute leukemia: A systematic review and meta-analysis.

Authors:  Yanfeng Liu; Pengcheng He; Feng Liu; Lili Shi; Huachao Zhu; Xiaoyan Cheng; Jing Zhao; Yuan Wang; Mei Zhang
Journal:  Mol Clin Oncol       Date:  2014-01-24

6.  Universal monitoring of minimal residual disease in acute myeloid leukemia.

Authors:  Elaine Coustan-Smith; Guangchun Song; Sheila Shurtleff; Allen Eng-Juh Yeoh; Wee Joo Chng; Siew Peng Chen; Jeffrey E Rubnitz; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  JCI Insight       Date:  2018-05-03

Review 7.  Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemia.

Authors:  Alan S Gamis; Todd A Alonzo; John P Perentesis; Soheil Meshinchi
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

8.  Cytogenetics and outcome of allogeneic transplantation in first remission of acute myeloid leukemia: the French pediatric experience.

Authors:  A-L Alloin; G Leverger; J-H Dalle; C Galambrun; Y Bertrand; A Baruchel; A Auvrignon; V Gandemer; C Ragu; A Loundou; C Bilhou-Nabera; M Lafage-Pochitaloff; N Dastugue; B Nelken; C Jubert; F Rialland; G Plat; C Pochon; J-P Vannier; P-S Rohrlich; J Kanold; P Lutz; A Sirvent; C Oudin; W Cuccuini; G Michel
Journal:  Bone Marrow Transplant       Date:  2016-12-12       Impact factor: 5.483

9.  A polymorphism in the 3'-untranslated region of the NPM1 gene causes illegitimate regulation by microRNA-337-5p and correlates with adverse outcome in acute myeloid leukemia.

Authors:  Chi Keung Cheng; Tsz Ki Kwan; Chi Ying Cheung; Kitty Ng; Pei Liang; Suk Hang Cheng; Natalie P H Chan; Rosalina K L Ip; Raymond S M Wong; Vincent Lee; Chi Kong Li; Sze Fai Yip; Margaret H L Ng
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

10.  Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol.

Authors:  Hideki Nakayama; Ken Tabuchi; Akio Tawa; Ichiro Tsukimoto; Masahiro Tsuchida; Akira Morimoto; Hiromasa Yabe; Keizo Horibe; Ryoji Hanada; Masue Imaizumi; Yasuhide Hayashi; Kazuko Hamamoto; Ryoji Kobayashi; Kazuko Kudo; Akira Shimada; Takako Miyamura; Hiroshi Moritake; Daisuke Tomizawa; Takashi Taga; Souichi Adachi
Journal:  Int J Hematol       Date:  2014-06-25       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.